Eli Lilly and Novo Nordisk are gearing up to release oral weight-loss pills in the U.S. next year, sparking competition in the obesity drug market dominated by weekly injections. Lilly’s recent trial results raised doubts about the efficacy of its pill compared to Novo’s, leading to anticipation for head-to-head trial data.
Doctors will soon compare Lilly and Novo’s pills in a head-to-head trial focusing on weight loss and blood sugar levels in patients with Type 2 diabetes. Lilly’s Chief Scientific Officer is confident in their pill’s performance, but Novo’s Chief Scientific Officer believes their data speaks for itself.
Despite Lilly’s shot being more effective than their oral drug, Novo’s pill has shown slightly better weight loss results. Analysts predict that oral drugs could represent 20% of the $80 billion GLP-1 obesity drug market by 2030, but uncertainties remain about patient preferences for pills over injections.
Lilly believes that oral drugs could become the primary treatment for obesity globally, with their pill offering advantages in manufacturing and convenience over Novo’s oral option. However, analysts have adjusted their sales estimates for Lilly’s drug following the trial results, shifting some market share to Novo’s pill.
The future of the obesity drug market remains uncertain, with both companies vying for dominance in the emerging oral drug space. Lilly’s confidence in their pill’s science contrasts with the market’s unpredictable dynamics, leaving analysts and investors eager to see how the competition unfolds.
Read more at CNBC
1. U.S. stocks closed higher on Thursday, with the S&P 500 reaching a new record high. The Dow Jones Industrial Average rose 0.1%, the S&P 500 gained 0.3%, and the Nasdaq Composite climbed 0.5%.
2. Tesla reported better-than-expected earnings for the second quarter, with revenue hitting $11.96 billion. The electric vehicle company also posted a net income of $1.45 billion.
3. Moderna announced that its Covid-19 vaccine generated $4.2 billion in revenue in the second quarter. The company expects sales to increase in the coming months as more countries purchase their vaccine doses.: Obesity pills from Eli Lilly, Novo Nordisk near US launch